JP2020518676A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518676A5
JP2020518676A5 JP2020511873A JP2020511873A JP2020518676A5 JP 2020518676 A5 JP2020518676 A5 JP 2020518676A5 JP 2020511873 A JP2020511873 A JP 2020511873A JP 2020511873 A JP2020511873 A JP 2020511873A JP 2020518676 A5 JP2020518676 A5 JP 2020518676A5
Authority
JP
Japan
Prior art keywords
composition
iii
hind
weight percentage
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511873A
Other languages
English (en)
Japanese (ja)
Other versions
JP7183253B2 (ja
JP2020518676A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031436 external-priority patent/WO2018204930A1/en
Publication of JP2020518676A publication Critical patent/JP2020518676A/ja
Publication of JP2020518676A5 publication Critical patent/JP2020518676A5/ja
Priority to JP2022186393A priority Critical patent/JP7433402B2/ja
Application granted granted Critical
Publication of JP7183253B2 publication Critical patent/JP7183253B2/ja
Priority to JP2024016340A priority patent/JP7698083B2/ja
Priority to JP2025098540A priority patent/JP2025123344A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511873A 2017-05-05 2018-05-07 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造 Active JP7183253B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022186393A JP7433402B2 (ja) 2017-05-05 2022-11-22 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造
JP2024016340A JP7698083B2 (ja) 2017-05-05 2024-02-06 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造
JP2025098540A JP2025123344A (ja) 2017-05-05 2025-06-12 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501984P 2017-05-05 2017-05-05
US62/501,984 2017-05-05
PCT/US2018/031436 WO2018204930A1 (en) 2017-05-05 2018-05-07 Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186393A Division JP7433402B2 (ja) 2017-05-05 2022-11-22 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造

Publications (3)

Publication Number Publication Date
JP2020518676A JP2020518676A (ja) 2020-06-25
JP2020518676A5 true JP2020518676A5 (enExample) 2021-07-26
JP7183253B2 JP7183253B2 (ja) 2022-12-05

Family

ID=64016742

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020511873A Active JP7183253B2 (ja) 2017-05-05 2018-05-07 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造
JP2022186393A Active JP7433402B2 (ja) 2017-05-05 2022-11-22 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造
JP2024016340A Active JP7698083B2 (ja) 2017-05-05 2024-02-06 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造
JP2025098540A Pending JP2025123344A (ja) 2017-05-05 2025-06-12 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022186393A Active JP7433402B2 (ja) 2017-05-05 2022-11-22 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造
JP2024016340A Active JP7698083B2 (ja) 2017-05-05 2024-02-06 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造
JP2025098540A Pending JP2025123344A (ja) 2017-05-05 2025-06-12 トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造

Country Status (11)

Country Link
US (5) US10611787B2 (enExample)
EP (3) EP3618827B1 (enExample)
JP (4) JP7183253B2 (enExample)
CN (2) CN117462558A (enExample)
AU (2) AU2018263965B2 (enExample)
CA (1) CA3062369A1 (enExample)
ES (1) ES2959891T3 (enExample)
PL (1) PL3618827T3 (enExample)
RU (1) RU2019138773A (enExample)
SG (1) SG11201910043PA (enExample)
WO (1) WO2018204930A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618827B1 (en) * 2017-05-05 2023-07-26 Bold Therapeutics Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof
US20230024119A1 (en) * 2019-12-05 2023-01-26 Bold Therapeutics, Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
EP4247413A4 (en) * 2020-11-18 2024-10-09 Bold Therapeutics Inc. USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612291A1 (de) * 1996-03-28 1997-10-02 Bernhard K Prof Dr Dr Keppler Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe
DE10103565B4 (de) * 2001-01-26 2007-06-14 Faustus Forschungs Cie. Translational Cancer Research Gmbh Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus
ES2441262T3 (es) 2007-06-11 2014-02-03 Niiki Pharma Inc. Método de fabricación de un complejo de rutenio
EP2509599B1 (en) * 2009-12-11 2014-08-13 Niiki Pharma Inc. Method for treating pancreatic cancer
JP5826259B2 (ja) 2010-06-22 2015-12-02 フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ ルテニウムベース錯体
WO2012012305A2 (en) 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
US10766915B2 (en) 2013-03-15 2020-09-08 Sherri Ann McFARLAND Metal-based coordination complexes as photodynamic compounds and their use
CN103601759B (zh) 2013-10-18 2015-08-19 武汉利宝瑞医药科技有限公司 一种用于治疗肿瘤的钌(iii)络合物的制备方法
US10342801B2 (en) * 2015-06-23 2019-07-09 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
EP3618827B1 (en) * 2017-05-05 2023-07-26 Bold Therapeutics Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof

Similar Documents

Publication Publication Date Title
JP2019524883A5 (enExample)
JP2023506691A5 (enExample)
DE69225484T2 (de) Gallium iii komplexe, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten
JP2020503009A5 (enExample)
JP2006501176A5 (enExample)
JP2006182786A5 (enExample)
JP2020536884A5 (enExample)
JP2014515735A5 (enExample)
JP2009502961A5 (enExample)
JPH04327596A (ja) 新規トランス−Ｐｔ（ＩＶ）化合物
JP2021524482A5 (enExample)
JPH0354117B2 (enExample)
JP2015508092A5 (enExample)
JP2019527724A5 (enExample)
EP0719144A1 (en) Trans platinum(iv) complexes
JP2024502178A5 (enExample)
RU2019138773A (ru) Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций
US20170260222A1 (en) Crystalline forms of ferric maltol
JP2018536716A5 (enExample)
EP2752414A1 (en) Crystalline form of apixaban
CN102232070A (zh) (r)-5-((e)-2-(吡咯烷-3-基乙烯基)嘧啶的合成和新的盐形式
JP6738350B2 (ja) 尿酸輸送体阻害剤のナトリウム塩およびその結晶形
CN1214029C (zh) 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物
JP5179628B2 (ja) ４価白金錯体及びそれを含む医薬組成物
EP1721610B1 (en) Composition containing benzamidine derivative and method for stabilizing benzamidine derivative